StockNews.com Initiates Coverage on Ekso Bionics (NASDAQ:EKSO)

Stock analysts at StockNews.com assumed coverage on shares of Ekso Bionics (NASDAQ:EKSO) in a research note issued to investors on Thursday. The firm set a “hold” rating on the stock.

Several other equities research analysts have also recently commented on EKSO. Lake Street Capital lowered their price target on Ekso Bionics from $2.50 to $2.00 and set a “buy” rating for the company in a research note on Tuesday, October 29th. HC Wainwright reissued a “buy” rating and issued a $9.00 target price on shares of Ekso Bionics in a research report on Tuesday, January 14th.

Ekso Bionics Trading Down 3.3 %

Ekso Bionics stock opened at $0.62 on Thursday. Ekso Bionics has a 12 month low of $0.50 and a 12 month high of $2.35. The company has a quick ratio of 2.14, a current ratio of 2.81 and a debt-to-equity ratio of 0.28. The stock has a market cap of $13.64 million, a P/E ratio of -0.95 and a beta of 1.47. The company’s fifty day simple moving average is $0.66 and its 200-day simple moving average is $0.92.

Ekso Bionics (NASDAQ:EKSO) last issued its earnings results on Monday, October 28th. The company reported ($0.10) EPS for the quarter, missing analysts’ consensus estimates of ($0.08) by ($0.02). Ekso Bionics had a negative net margin of 62.95% and a negative return on equity of 83.09%. The firm had revenue of $4.13 million during the quarter, compared to analysts’ expectations of $6.00 million. During the same quarter last year, the firm earned ($0.24) EPS. As a group, sell-side analysts forecast that Ekso Bionics will post -0.48 EPS for the current fiscal year.

About Ekso Bionics

Ekso Bionics Holdings, Inc designs, develops, sells, and rents exoskeleton products in the Americas, Germany, Poland, Europe, the Middle East, Africa, the Asia Pacific, and internationally. It operates in two segments, EksoHealth and EksoWorks. The EksoHealth segment designs, engineers, manufactures, and markets exoskeletons for applications in the medical markets.